Follicle regulatory protein (FRP) is secreted by the granulosa cell of the ovary and plays a role in modulating follicle development. A dual epitope immunoassay using two murine monoclonal antibodies, isotype IgG1 (raised against porcine FRP), in tandem was developed to measure FRP in serum. The levels of FRP in the serum of women with granulosa cell tumors, normal, menstruating women, and postmenopausal women were determined. The levels of FRP were elevated in the serum of 79% of the women with granulosa cell tumors compared to the normal controls. FRP levels in serial samples from women with granulosa cell tumors generally correlated with the clinical course of the disease. Thus, FRP may provide a useful marker for granulosa cell tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0090-8258(90)90372-rDOI Listing

Publication Analysis

Top Keywords

granulosa cell
24
cell tumors
16
women granulosa
12
follicle regulatory
8
regulatory protein
8
marker granulosa
8
frp serum
8
levels frp
8
frp
7
granulosa
6

Similar Publications

Ovarian granulosa cells produce a variety of biologically active compounds in addition to steroid hormones that include numerous families of growth factors, cytokines and adipokines. Many of these function as endocrine, paracrine and autocrine hormones to regulate ovarian activity. The goal of this review is to provide an update on the evidence in domestic animals on how FSH, insulin and IGF1 regulate the function of granulosa cells with a focus on ovarian steroidogenesis and cell proliferation with comparisons across six domestic animals: pigs, cattle, horses, water buffalo, goats and sheep.

View Article and Find Full Text PDF

The role of Anti-Müllerian hormone in women health.

Ginekol Pol

January 2025

Department of Clinical Dietetics, Faculty of Health Sciences, Medical University of Warsaw, Poland, Poland.

Anti-Müllerian hormone (AMH), also known as Müller duct inhibitory factor and primarily known for its role in sexual differentiation. In female fetuses, AMH production by granulosa cells begins around the 36th week of gestation and continues in women until menopause. It is becoming more significant in the endocrine and gynecological diagnosis of adult women.

View Article and Find Full Text PDF

Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary.

Int J Gynecol Cancer

January 2025

Memorial Sloan Kettering Cancer Center, Department of Medicine, Gynecologic Medical Oncology Service, New York, NY, USA; Weill Cornell Medical College, Department of Medicine, New York, NY, USA. Electronic address:

Objective: We sought to determine the safety and efficacy of the oral progesterone antagonist onapristone in combination with anastrozole in patients with recurrent progesterone receptor-positive adult-type granulosa cell tumor of the ovary.

Methods: This was a single-institution phase II study of patients with progesterone receptor-positive adult-type granulosa cell tumor who received at least 1 prior line of chemotherapy. Patients were enrolled from November 2021 to August 2022 and tissue was evaluated for progesterone receptor status via immunohistochemistry.

View Article and Find Full Text PDF

Rare malignant ovarian tumors: a review.

Jpn J Clin Oncol

January 2025

Department of Gynecology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

There are many histologic types of gynecologic malignancies. I reviewed three rare ovarian tumor types that have poor prognoses. Ovarian mesonephric-like adenocarcinoma (MLA) is a newly described histological type known for its aggressive behavior.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!